Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy

Neoadjuvant therapy; Peptide receptor radionuclide therapy; Progression

Detalles Bibliográficos
Autores: Garcia‑Carbonero, Rocio, Simo Perdigo, Marc, Del Olmo García, Maria Isabel, Jimenez-Fonseca, Paula, Pubul Núñez, Virginia, Capdevila Castillon, Jaume, Grande, Enrique, Carmona-Bayonas, Alberto
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Departament de Salut de la Generalitat de Catalunya (DS)
Repositorio:Scientia. Dipòsit d'Informació Digital del Departament de Salut
OAI Identifier:oai:scientiasalut.gencat.cat:11351/8015
Acceso en línea:https://hdl.handle.net/11351/8015
Access Level:acceso abierto
Palabra clave:Tumors neuroendocrins - Radioteràpia
Tumors neuroendocrins - Diagnòstic
Avaluació de resultats (Assistència sanitària)
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neuroendocrine Tumors
Other subheadings::Other subheadings::Other subheadings::/radiotherapy
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::tumores neuroendocrinos
Otros calificadores::Otros calificadores::Otros calificadores::/radioterapia
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
id ES_dd79797e7a2b4e266dde5584cf0120f6
oai_identifier_str oai:scientiasalut.gencat.cat:11351/8015
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy
title Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy
spellingShingle Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy
Garcia‑Carbonero, Rocio
Tumors neuroendocrins - Radioteràpia
Tumors neuroendocrins - Diagnòstic
Avaluació de resultats (Assistència sanitària)
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neuroendocrine Tumors
Other subheadings::Other subheadings::Other subheadings::/radiotherapy
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::tumores neuroendocrinos
Otros calificadores::Otros calificadores::Otros calificadores::/radioterapia
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
title_short Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy
title_full Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy
title_fullStr Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy
title_full_unstemmed Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy
title_sort Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy
dc.creator.none.fl_str_mv Garcia‑Carbonero, Rocio
Simo Perdigo, Marc
Del Olmo García, Maria Isabel
Jimenez-Fonseca, Paula
Pubul Núñez, Virginia
Capdevila Castillon, Jaume
Grande, Enrique
Carmona-Bayonas, Alberto
author Garcia‑Carbonero, Rocio
author_facet Garcia‑Carbonero, Rocio
Simo Perdigo, Marc
Del Olmo García, Maria Isabel
Jimenez-Fonseca, Paula
Pubul Núñez, Virginia
Capdevila Castillon, Jaume
Grande, Enrique
Carmona-Bayonas, Alberto
author_role author
author2 Simo Perdigo, Marc
Del Olmo García, Maria Isabel
Jimenez-Fonseca, Paula
Pubul Núñez, Virginia
Capdevila Castillon, Jaume
Grande, Enrique
Carmona-Bayonas, Alberto
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Capdevila J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron-Teknon Barcelona, Barcelona, Spain. [Grande E] Department of Medical Oncology, MD Anderson Cancer Center, Madrid, Spain. [García-Carbonero R] Department of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. [Simó M] Servei de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Del Olmo-García MI] Department of Endocrinology, Hospital Universitario y Politécnico la Fe de Valencia, Valencia, Spain. [Jiménez-Fonseca P] Department of Medical Oncology, Hospital Universitario Central de Asturias, ISPA, Madrid, Spain. [Carmona-Bayonas A] Department of Hematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, Murcia, Spain. [Pubul V] Department of Nuclear Medicine Department, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Tumors neuroendocrins - Radioteràpia
Tumors neuroendocrins - Diagnòstic
Avaluació de resultats (Assistència sanitària)
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neuroendocrine Tumors
Other subheadings::Other subheadings::Other subheadings::/radiotherapy
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::tumores neuroendocrinos
Otros calificadores::Otros calificadores::Otros calificadores::/radioterapia
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
topic Tumors neuroendocrins - Radioteràpia
Tumors neuroendocrins - Diagnòstic
Avaluació de resultats (Assistència sanitària)
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neuroendocrine Tumors
Other subheadings::Other subheadings::Other subheadings::/radiotherapy
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::tumores neuroendocrinos
Otros calificadores::Otros calificadores::Otros calificadores::/radioterapia
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
description Neoadjuvant therapy; Peptide receptor radionuclide therapy; Progression
publishDate 2022
dc.date.none.fl_str_mv 2022
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/8015
url https://hdl.handle.net/11351/8015
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv The Oncologist;27(4)
https://doi.org/10.1093/oncolo/oyab041
dc.rights.none.fl_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Oxford University Press
publisher.none.fl_str_mv Oxford University Press
dc.source.none.fl_str_mv Scientia
reponame:Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname:Departament de Salut de la Generalitat de Catalunya (DS)
instname_str Departament de Salut de la Generalitat de Catalunya (DS)
reponame_str Scientia. Dipòsit d'Informació Digital del Departament de Salut
collection Scientia. Dipòsit d'Informació Digital del Departament de Salut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421863442055168
spelling Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand TherapyGarcia‑Carbonero, RocioSimo Perdigo, MarcDel Olmo García, Maria IsabelJimenez-Fonseca, PaulaPubul Núñez, VirginiaCapdevila Castillon, JaumeGrande, EnriqueCarmona-Bayonas, AlbertoTumors neuroendocrins - RadioteràpiaTumors neuroendocrins - DiagnòsticAvaluació de resultats (Assistència sanitària)DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neuroendocrine TumorsOther subheadings::Other subheadings::Other subheadings::/radiotherapyANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment OutcomeENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::tumores neuroendocrinosOtros calificadores::Otros calificadores::Otros calificadores::/radioterapiaTÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamientoNeoadjuvant therapy; Peptide receptor radionuclide therapy; ProgressionTeràpia neoadjuvant; Teràpia amb radionúclids del receptor de pèptids; ProgressióTerapia neoadyuvante; Terapia con radionúclidos del receptor de péptidos; ProgresiónBackground The aim of this study was to provide a guidance for the management of neuroendocrine tumors (NETs) in clinical practice. Material and Methods Nominal group and Delphi techniques were used. A steering committee of 8 experts reviewed the current management of NETs, identified controversies and gaps, critically analyzed the available evidence, and formulated several guiding statements for clinicians. Subsequently, a panel of 26 experts, was selected to test agreement with the statements through 2 Delphi rounds. Items were scored on a 4-point Likert scale from 1 = totally agree to 4 = totally disagree. The agreement was considered if ≥75% of answers pertained to Categories 1 and 2 (consensus with the agreement) or Categories 3 and 4 (consensus with the disagreement). Results Overall, 132 statements were proposed, which incorporated the following areas: (1) overarching principles; (2) progression and treatment response criteria; (3) advanced gastro-enteric NETs; (4) advanced pancreatic NETs; (5) advanced NETs in other locations; (6) re-treatment with radioligand therapy (RLT); (7) neoadjuvant therapy. After 2 Delphi rounds, only 4 statements lacked a clear consensus. RLT was not only recommended in the sequencing of different NETs but also as neoadjuvant treatment, while several indications for retreatment with RLT were also established. Conclusion This document sought to pull together the experts’ attitudes when dealing with different clinical scenarios of patients suffering from NETs, with RLT having a specific role where evidence-based data are limited.This project was funded by Advanced Accelerator Applications, a Novartis company.Oxford University PressInstitut Català de la Salut[Capdevila J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron-Teknon Barcelona, Barcelona, Spain. [Grande E] Department of Medical Oncology, MD Anderson Cancer Center, Madrid, Spain. [García-Carbonero R] Department of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. [Simó M] Servei de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Del Olmo-García MI] Department of Endocrinology, Hospital Universitario y Politécnico la Fe de Valencia, Valencia, Spain. [Jiménez-Fonseca P] Department of Medical Oncology, Hospital Universitario Central de Asturias, ISPA, Madrid, Spain. [Carmona-Bayonas A] Department of Hematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, Murcia, Spain. [Pubul V] Department of Nuclear Medicine Department, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, SpainVall d'Hebron Barcelona Hospital Campus202220222022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/11351/8015Scientiareponame:Scientia. Dipòsit d'Informació Digital del Departament de Salutinstname:Departament de Salut de la Generalitat de Catalunya (DS)InglésThe Oncologist;27(4)https://doi.org/10.1093/oncolo/oyab041Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:scientiasalut.gencat.cat:11351/80152026-06-12T09:38:37Z
score 15,811543

Similares en LA Referencia